WO2007046868A3 - Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques - Google Patents

Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques Download PDF

Info

Publication number
WO2007046868A3
WO2007046868A3 PCT/US2006/019357 US2006019357W WO2007046868A3 WO 2007046868 A3 WO2007046868 A3 WO 2007046868A3 US 2006019357 W US2006019357 W US 2006019357W WO 2007046868 A3 WO2007046868 A3 WO 2007046868A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
thiazolidine derivatives
mammal
formula
disclosed
Prior art date
Application number
PCT/US2006/019357
Other languages
English (en)
Other versions
WO2007046868A2 (fr
Inventor
Jianmin Fu
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc
Jianmin Fu
Shifeng Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Jianmin Fu, Shifeng Liu filed Critical Xenon Pharmaceuticals Inc
Publication of WO2007046868A2 publication Critical patent/WO2007046868A2/fr
Publication of WO2007046868A3 publication Critical patent/WO2007046868A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention concerne des procédés de traitement d’un état ou d’une maladie à médiation SCD chez un mammifère, de préférence un être humain, lesdits procédés comprenant l’administration à un mammifère en ayant besoin d’un composé de formule (I) : dans laquelle p, K, J, W, V, R2, R3, R4, R4a, R5, R5a et R6 sont tels que définis dans le présent document. L’invention concerne également des compositions pharmaceutiques comprenant les composés de formule (I).
PCT/US2006/019357 2005-05-19 2006-05-19 Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques WO2007046868A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68292705P 2005-05-19 2005-05-19
US60/682,927 2005-05-19

Publications (2)

Publication Number Publication Date
WO2007046868A2 WO2007046868A2 (fr) 2007-04-26
WO2007046868A3 true WO2007046868A3 (fr) 2007-07-12

Family

ID=37866350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019357 WO2007046868A2 (fr) 2005-05-19 2006-05-19 Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques

Country Status (1)

Country Link
WO (1) WO2007046868A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098146B2 (en) 2020-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143824A1 (fr) * 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Dérivés de l'azacyclopentane utilisés en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2459568A4 (fr) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
EP2475367A1 (fr) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique Nouveaux inhibiteurs de stearoyl-coa-desaturase-1 et leurs utilisations
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766000A2 (fr) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Procédés d'utilisation d'antagonistes de scd1
BR112014029365A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche inibidores seletivos de células indiferenciadas
WO2016044771A1 (fr) * 2014-09-18 2016-03-24 Abbvie Inc. Inhibiteurs de hat et procédés pour leur utilisation
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496104A1 (fr) * 1978-03-22 1982-06-18 Roussel Uclaf Nouveaux produits de la serie de la 3-(piperidin-4-yl) 2h-indol-2-one, et procede pour leur preparation
JPH04182481A (ja) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd ロダニン誘導体
WO2001062954A2 (fr) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2496104A1 (fr) * 1978-03-22 1982-06-18 Roussel Uclaf Nouveaux produits de la serie de la 3-(piperidin-4-yl) 2h-indol-2-one, et procede pour leur preparation
JPH04182481A (ja) * 1990-11-19 1992-06-30 Nisshin Flour Milling Co Ltd ロダニン誘導体
WO2001062954A2 (fr) * 2000-02-24 2001-08-30 Xenon Genetics, Inc. Methodes et compositions utilisant la stearoyl-coa desaturase pour identifier des agents therapeutiques reduisant les triglycerides
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199232, Derwent World Patents Index; AN 1992-265155, XP002426480 *
F. C. BROWN ET AL: "Rhodanine Derivatives", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 73, 1951, pages 2357 - 2359, XP002426478 *
H. SINGH AHUJA ET AL: "Differential Effects of Rexinoids and Thiazolidinediones on Metabolic Gene Expression in Diabetic Rodents", MOLECULAR PHARMACOLOGY, vol. 59, no. 4, 2001, pages 765 - 773, XP002426477 *
J. TONELLI ET AL: "Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes", DIABETES, vol. 53, no. 6, June 2004 (2004-06-01), pages 1621 - 1629, XP002426476 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098146B2 (en) 2020-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Also Published As

Publication number Publication date
WO2007046868A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007046868A3 (fr) Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2007130075A8 (fr) Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
WO2006086447A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200624427A (en) Heterocyclic derivatives and their use as therapeutic agents
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
WO2005011653A3 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006125181A3 (fr) Derives piperidiniques: utilisation comme agents therapeutiques
WO2005011655A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
WO2006125194A3 (fr) Derives de piperazine et leurs utilisations en tant qu'agents therapeutiques
WO2005011654A3 (fr) Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
WO2007136746A3 (fr) Composés macrocycliques et leurs utilisations en tant qu'agents thérapeutiques
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06844101

Country of ref document: EP

Kind code of ref document: A2